网站首页|本系概况|机构设置|学科建设|师资队伍|成果转化|学术动态|规章制度|焦点
 
 
当前位置: 网站首页>>师资队伍>>学术带头人>>正文
 

张英起
2015-09-02 09:23     (点击: )

张英起

男,博士,现为第四军医大学药学系生物制药学教研室主任,教授,博士研究生导师。1983年毕业于第四军医大学医疗系,1986年和1991年分别获得第四军医大学生物化学与分子生物学专业硕士和博士学位。现任国家肿瘤生物学国家重点实验室(第四军医大学)肿瘤靶向单元PI;任中国生物化学与分子生物学学会工业分会副理事长;全军生物技术专业委员会副主任委员;中国药学会生化与生物技术药物专业委员会委员;陕西省生物化学与分子生物学学会常务理事。

研究方向抗肿瘤治疗的基础研究及基因工程药物的开发研究

承担国家课题

1、重组人干扰素a2a与肿瘤新生血管结合多肽NGR融合蛋白的临床前研究

“重大新药创制”科技重大专项(No. 2009ZX09102-225)负责人

2、保密课题“重大新药创制”科技重大专项—军队特需药品保密专项课题(课题编号:2008ZXJ09004-025)负责人

3、Foxp3通过UXT负向调控NF-κB的转录活性及其复合物在调节性T细胞中的生物学意义国家自然科学基金(No.30972672)负责人

4、肿瘤内源性GDF15通过DC诱导肿瘤免疫逃逸的机制研究国家自然科学基金(No.81171978)负责人

5、GDF-15诱导巨噬细胞向M2亚型激化促进肿瘤免疫逃逸及其机制研究国家自然科学基金(No. 81472649)负责人

代表性论著

1.Cun Zhang, Yujin Xu, Qiang Hao,Shuning Wang, Hong Li, Jialin Li, Yuan Gao, Meng Li, Weina Li,Xiaochang Xue,Shouzhen Wu,Yingqi Zhang, Wei Zhang. FOXP3 suppresses breastcancer metastasis through downregulation of CD44.IntJ Cancer.2015 Sep;137(6):1279-90.

2.Zhen Shu, Jing Li a, Nan Mu, YuanGao, Tonglie Huang, Ying Zhang, Zenglu Wang, Meng Li , Qiang Hao, Weina Li,Liqing He, Cun Zhang, Wei Zhang, Xiaochang Xue ,Yingqi Zhang,Expression, purification and characterization of galectin-1 in Escherichia Coli.Protein Expression and Purification99 (2014) 58–63

3.Weina Li, Qiang Hao, Liqing He,Jieru, Meng, Meng Li, Xiaochang Xue, Cun, Zhang, Hong Li, Wei Zhang &YingqiZhang, Recombinant IFN-α2a-NGR exhibits higher inhibitory function ontumor neovessels formation compared with IFN-α2a in vivo and in vitro.CytotechnologyDOI 10.1007/s10616-014-9743-y

4.Zhao W,Zhang C,Shi M,Zhang J,Li M,Xue X,Zhang Z,Shu Z,Zhu J,Mu N,Li W,Hao Q,Wang Z,Gong L,Zhang W,Zhang Y. The DDR2-Annexin A2-MMP13 looppromotes joint destruction in arthritis through promoting migration andinvasion of fibroblast-like synoviocytes.Arthritis Rheumatol.66(9):2355-2367.2014

5.JiangC, Niu J, Li M, Teng Y, Wang H,Zhang Y.TumorVasculature-Targeted Recombinant Mutated Human TNF-α Enhanced the AntitumorActivity of Doxorubicin by Increasing Tumor Vessel Permeability in MouseXenograft Models.PLoS One. Jan 22;9(1):e87036.2014

6.HaoQ, Zhang C, Gao Y, Wang S, Li J, Li M, Xue X, Li W, Zhang W,Zhang Y.FOXP3 inhibits NF-κB activity and hence COX2 expressionin gastric cancer cells.Cell Signal.Mar;26(3):564-9. 2014

7.LiW, Wang L, Jiang C, Li H, Zhang K, Xu Y, Hao Q, Li M, Xue X, Qin X, Zhang C,Wang H, Zhang W,Zhang Y.UXT is a novel regulatory factor of regulatory T cellsassociated with Foxp3.Eur J Immunol. Feb;44(2):533-44.2014

8.ZhangC, Wang W, Qin X, Xu Y, Huang T, Hao Q, Li W, Wu S,Zhang Y*.B7-H1 protein vaccine induces protective and therapeuticantitumor responses in SP2/0 myeloma-bearing mice.Oncol Rep. Nov;30(5):2442-8. 2013

9.LiW, Ran Y, Li M, Zhang K, Qin X, Xue X, Zhang C, Hao Q, Zhang W,Zhang Y.Mimotope vaccination for epitope-specific induction ofanti-VEGF antibodies.BMC Biotechnol. Sep 27;13:77. 2013

10.Zhou Z, Li W, Song Y, Wang L, Zhang K, Yang J, Zhang W, Su H,ZhangY.Growth differentiation factor-15suppresses maturation and function of dendritic cells and inhibitstumor-specific immune response.PLoSOne. Nov 13;8(11):e78618. 2013

11.Tian-Jiao Xu, Qi Wang, Xiao-Wen Ma, Zhen Zhang, Wei Zhang,Xiao-chang Xue, cun Zhang, Qiang hao, Wei-na li,Ying-QiZhang, Meng li, A novel dimeric thymosin beta 4 with enhancedactivities accelerates the rate of wound healing.Drug Design, Development and Therapy2013:7 1075–1088.

12.Wu K, Xue X, Li M, Qin X, Zhang C, Li W, Hao Q, Wang Z, Liu Q, ZhangW,Zhang Y.High level expression,purification and characterization of recombinant CCR5 as a vaccine candidateagainst HIV.Protein Expr Purif.Jun;89(2):124-30. 2013

13.Qiang Hao, Weina Li, Cun Zhang, Xin Qin, Xiaochang Xue, Meng Li,Zhen Shu, Tianjiao Xu, Yujin Xu, Weihua Wang, Wei Zhang,Yingqi Zhang. TNFα inducedFOXP3–NFkB interaction dampens the tumor suppressor role of FOXP3 in gastric cancer cells.Biochemical and Biophysical Research Communications. 430(1):436-441. 2013.

14.Xin Q, Cun Z, Xiaochang X, Meng L, Weina L, Qiang H,Yingqi Z,Zhen Y, Wei Z.Identification of a novel Peptide ligand of human transfrrin receptor 1 fortargeted tumor delivery drug.Protein Pept Lett.20(1):96-101.2013.

Qiang Hao, Xiaozhao Lu, Nannan Liu, Xiaochang Xue, Meng Li, CunZhang, Xin Qin, Weina Li, Zhen Shu, Wei Zhang,YingqiZhang. Posttranscriptional deregulation of Srcdue to aberrant miR34a and miR203 contributes to gastric cancer development.BMB

Reports.Jun;46(6):316-21.2013

15.Xiao-Chang Xue, Zhen Yan, Wei-Na Li, Meng Li, Xin Qin, Cun Zhang, Qiang Hao, Zeng-Lu Wang, Ning Zhao, Wei Zhang, andYing-Qi Zhang. Construction, expression and characterization of thymosin alpha 1 tandem repeats in Escherichia coli.Biomed Research International,2013;2013:720285. doi: 10.1155/2013/720285. Epub 2013 Feb 28.

16.Li M, Xu T, Zhang Z, Xue X, Zhang C, Qin X, Li W, Hao Q, Zhang W,ZhangY.Phase II multicenter, randomized,double-blind study of recombinant mutated human tumor necrosis factor-α incombination with chemotherapies in cancer patients.Cancer Sci.Feb;103(2):288-95. 2012

17.Li W, Song L, Wu S, Xue X, Zhang L, He L, Han W, Wang Q, Ling R,Zhang W, Yan Z,Zhang Y.Expression, purification and characterization of a novelsoluble human thymosin alpha1 concatemer exhibited a stronger stimulation onmice lymphocytes proliferation and higher anti-tumor activity.Int J Biol Sci.7(5):618-28. 2011

18.Wei-Hua Wang, Chang-Li Jiang, Wei Yan, Yu-Hai Zhang, Jiang-Tao Yang,Cun Zhang, Bo Yan, Wei Zhang, Wei Han, Jun-Zhi Wang,Ying-Qi Zhang. FOXP3 expression andclinical characteristics of hepatocellular carcinoma.World JGastroenterol. 16(43): 5502-5509.2010

19.Li M, Qin X, Xue X, Zhang C, Yan Z, Han W,Komarck C, Wang TD,Zhang Y.Safety evaluation andpharmacokinetics of a novel human tumor necrosis factor-alpha exhibited ahigher antitumor activity and a lower systemic toxicity.AnticancerDrugs.2010 Mar;21(3):243-51.

20.Zhang XY, Wang S, Yan Z,Zhang YQ,Wan Y, Zhang B, Wang LF, Chai YB, Wei JG. Promoter cloning and characterizationof the rabbit BK channel beta1 subunit gene.Gene.2009 Jun1;438(1-2):33-9.

21.Liu N, Wang L, Li X, Yang Q, Liu X, Zhang J,Zhang J, Wu Y, Ji S,Zhang Y,Yang A, Han H, Yao L.N-Mycdownstream-regulated gene 2 is involved in p53-mediated apoptosis.NucleicAcids Res.2008 Sep;36(16):5335-49.

22.Xue X, Feng G, Li M, Qin X, Wu S, Zhang C, YouY, Wang W, Jiang C, Liu Y, Zhu W, Ran Y, Zhang Z, Yan Z, Han W,Zhang Y.Amelioration of experimental autoimmune encephalomyelitis by BLySautovaccine.Vaccine.Vaccine.2008 Jun 2;26(23):2873-81.

23.Wang L, Liu N, Yao L, Li F, Zhang J, Deng Y, LiuJ, Ji S, Yang A, Han H,Zhang Y,Zhang J, Han W, Liu X. NDRG2 isa new HIF-1 target gene necessary for hypoxia-induced apoptosis in A549 cells.CellPhysiol Biochem.2008;21(1-3):239-50.

24.Wang T, Zhao J, Ren JL, Zhang L, Wen WH, ZhangR, Qin WW, Jia LT, Yao LB,Zhang YQ,Chen SY, Yang AG. Recombinantimmunoproapoptotic proteins with furin site can translocate and killHER2-positive cancer cells.Cancer Res. 2007;67(24):11830-9.

25.Liu N, Wang L, Liu X, Yang Q, Zhang J, Zhang W,Wu Y, Shen L,Zhang Y,Yang A, Han H, Zhang J, Yao L.Promotermethylation, mutation, and genomic deletion are involved in the decreased NDRG2expression levels in several cancer cell lines.Biochem Biophys ResCommun.2007;358(1):164-9

26.Huo Y, Li B,Zhang Y,WangS, Bao M, Gao X, Li D, Wang L, Yu Y, Wang J. Pre-clinical safety evaluation ofheat shock protein 65-MUC1 peptide fusion protein.Regul ToxicolPharmacol.2007 ;49(1):63-74.

27.Qin X, Li M, Xue X, Yan Z, Han W andZhangY.Identification of a novel peptideligand of human vascularendothelia growth factor receptor 3 for targeted tumor diagnosis and therapy.FEBSJournal.2007, 274(Sup 1): 281p

28.Li M, Han W, Zhang Q, Xue X, Wang Z,ZhangY.Development of a mimotope-based vaccine against CD20 antigen.ProteinPept Lett.2007;14(6):610-4.

29.Wan Y, Xue X, Li M, Zhang X, Qin X, Zhang C, YouY, Wang W, Jiang C, Wu S, Liu Y, Zhu W, Ran Y, Zhang Z, Han W,Zhang Y.Prepared and screened a modified TNF-alpha molecule as TNF-alpha autovaccine totreat LPS induced endotoxic shock and TNF-alpha induced cachexia in mouse.CellImmunol.2007 ;246(2):55-64.)

30.Tang L, Yan Z, Wan Y, Han W,Zhang Y.Myostatin DNA vaccine increases skeletal muscle mass and endurance in mice.MuscleNerve.2007;36(3):342-8.

31.Qin X, Wan Y, Li M, Xue X, Wu S, Zhang C, You Y,Wang W, Jiang C, Liu Y, Zhu W, Ran Y, Zhang Z, Han W,Zhang Y.Identification of a novel peptide ligand of human vascular endothelia growthfactor receptor 3 for targeted tumour diagnosis and therapy.JBiochem.2007 ;142(1):79-85.

32.J Meng, Z Yan, J Wu, L Li, X Xue, M Li, W Li, QHao, Y Wan, X Qin, W Han,Y Zhang. High-yield expression,purification and characterization of tumor-targeted IFN-α2a.Cytotherapy.2007;9(1):60-68.

33.Yan Z, Zhao N, Wang Z, Li B, Bao C, Shi J, HanW,Zhang Y.A mutated human tumor necrosis factor-alpha improvesthe therapeutic index in vitro and in vivo.Cytotherapy.2006;8(4):415-23.

34.Meng J, Ma N, Yan Z, Han W,Zhang Y.NGR enhanced the anti-angiogenic activity of tum-5.J Biochem.2006;140(2):299-304.

35.Li M, Yan Z, Han W,Zhang Y.Mimotope vaccination for epitope-specific induction of anti-CD20 antibodies.CellImmunol.2006;239(2):136-43

36.Yan Z, Lu L, Shi J, Bao C, Han W, Wu Y,ZhangY.Expression, refolding, and characterization of GFE peptide-fusedhuman interferon-alpha2a in Escherichia coli.Appl Biochem Biotechnol.2006 ;133(2):149-62.

37.Wu K, Xue X, Wang Z, Yan Z, Shi J, Han W,ZhangY.Construction, purification, and immunogenicity of recombinantcystein-cystein type chemokine receptor 5 vaccine.Protein Expr Purif.2006;49(1):108-13.

38.Wang H, Yan Z, Shi J, Han W,Zhang Y.Expression, purification, and characterizationof a neovasculature targetedrmhTNF-alpha in Escherichia coli.Protein Expr Purif.2006;45(1):60-5.

39.Hou D, Yan Z, Shi J, Han W,Zhang Y.Expression and one-step ion-exchange purification of (AAR)IL-8 (human IL-8receptor antagonist).Protein Expr Purif.2005;44(2):104-9.21.

Xue X, Wang Z, Yan Z, Shi J, Han W,ZhangY.Production and purification of recombinant human BLyS mutantfrom inclusion bodies.Protein Expr Purif.2005;42(1):194-9.

40.Hou D, Yan Z, Shi J, Han W,Zhang Y.Expression and one-step ion-exchange purification of (AAR)IL-8 (human IL-8receptor antagonist).Protein Expr Purif.2005;44(2):104-9.21.

41.Xue X, Wang Z, Yan Z, Shi J, Han W,ZhangY.Production and purification of recombinant human BLyS mutantfrom inclusion bodies.Protein Expr Purif.2005;42(1):194-9.

授权发明专利

1.肿瘤血管导向肽与人干扰素α-2b的融合蛋白的制备方法ZL200510043192.5

2.肿瘤新生血管特异性结合多肽与人α干扰素融合蛋白及制备 ZL02139537.3

3.肿瘤新生血管特异性结合多肽CRGDC与新型重组人肿瘤坏死因子nrhTNF融合蛋白及制备方法ZL200510096374

4.肿瘤新生血管特异性结合多肽与重组人Tum-5融合蛋白及其制备方法ZL200510096389.

5.人B细胞特异性膜分子CD20的12氨基酸模拟表位及其用该模拟表位构建的多肽表位疫苗ZL200510096370.0

6.人白细胞介素8拮抗蛋白及其制备方法ZL200510096373.4

7.破伤风毒素T细胞表位多肽与人B淋巴细胞刺激因子融合蛋白及其制备ZL200510096372.X

8.重组人His-TT-B7-H1IgV肿瘤疫苗及其制备方法ZL200610105039.5

9.一种Myostatin特异性抗体的治疗性疫苗及其制备方法ZL200610104728.4

10.基于模拟人血管内皮细胞生长因子VEGF表位的疫苗及其制ZL200810232718.8

11.重组胸腺素β4二串体蛋白及其制备方法 ZL200810232709.9

12.重组胸腺素α1二串体蛋白及其制备方法ZL200810232700.8

13.可溶性人程序性死亡蛋白-1-IgV及其制备方法ZL200810017236.0

14.一种基于人MUC1重复序列与GM-CSF融合表达的重组卡介苗ZL200910022248.7

15.重组半乳糖凝集素-1二串体蛋白及其制备方法ZL201010158056.1

16.机体保护多肽(BPC157肽)的制备方法ZL201110114806X

17.一种针对人TNF-α分子的自体疫苗的构建方法ZL2011103039461

18.人胸腺素β4二串体蛋白的制备方法ZL2011103763612

19.一种利用固相多肽合成法合成四肽异构体的方法及其应用ZL2011104366719

科研成果与获奖

1、肿瘤生物治疗新靶位、新策略、新药物的研究和临床应用 2012年获国家科技进步二等奖(2012-J-233-2-01-R-3)

2、肿瘤血管生成关键调控因子及其在临床诊治中的应用 2012年获陕西省科学技术一等奖(2012-1-29-D1)

3、注射用重组改构人肿瘤坏死因子2003年获国家I类新药证书(国药准字S20030019)

4、重组改构人肿瘤坏死因子2004年获陕西省科技进步一等奖

5、出版专著

6、1、黄晓峰,张远强,张英起主编《荧光探针技术 》人民军医出版社 北京2004.5

7、2、颜真,张英起,薛晓畅主编蛋白质研究技术 第四军医大学出版社 西安2007.1

8、

9、研究生培养

10、培养硕士研究生39名,博士研究生26名

关闭窗口

 
 · 热 点 新 闻
 

第四军医大药学系 版权所有 @2009
Coyright 2009 School of Pharmacy online.ALl Right Reserved